About Vetiqure

You are here:

Vetiqure – innovator in gentle cancer treatment

Vetiqure AB is a wholly owned subsidiary of Scandinavian ChemoTech AB, a dynamic Life Science company that focus on developing technologies and therapies for various cancer tumours and advanced pain control for cancer. The Company has extensive experience in Tumour Specifik Electroporation™ (TSE), which forms the basis of the Company’s therapeutic areas. Currently, the Company is offering treatments for a various forms of cancer tumours. The Company is based at Medicon Village in Lund, Sweden.

Launching the vetIQure™

Following extensive research and development, Vetiqure AB recently launched the vetIQure™ device. With its new patented technology, TSE (Tumour Specific Electroporation), it offers gentle yet effective and flexible treatments capabilities. vetIQure™ has been designed to achieve positive clinical outcomes on a level previously not possible. vetIQure™, is designed for animals based on a technology developed to treat humans. TSE makes it possible to treat non-responsive tumours and tumours in sensitive locations. Read more»

Next steps

vetIQure™ has now been launched and introduced to the veterinarian market and we are looking forward to close collaborations with both customers and distributors in Europe and the rest of the world.

Our heart and soul

By being devoted to clinical development and scientific excellence, Vetiqure AB aspires to be a force for better cancer care for our pets. Our aim is to always deliver cost and treatment-efficient technologies that improve the quality of life of those suffering from cancer, and their owners.

Our vision is to develop therapies for tomorrow and make them accessible to cancer patients where other treatments – for financial or medical reasons – are not available, or where the side effects are too severe. To achieve this, our strategy is to further develop our technology to make it more effective, easier to use, better adapted to clinical environments and suitable for treatment of a wider spectrum of illnesses and conditions.

What we believe

Many medical technical companies focus on science and clinical outcomes, but put less emphasis on the cost for the healthcare sector. At Vetiqure, we want to address both these issues. We believe that it is possible to provide cancer treatment with a solid scientific base and excellent clinical outcomes that are cost-efficient enough to be made available to everyone who needs them.

Strategic development

By using the global cancer epidemic as a strategic point of departure when developing our products, we want to adapt our unique method to ensure that it can excel both clinically and financially in countries where access to modern cancer treatment is limited. At Vetiqure, we are also developing treatment methods for indications where existing therapies often fail or are associated with great suffering or severe side effects.